Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oric Pharmaceuticals Inc
(NQ:
ORIC
)
9.580
+0.390 (+4.24%)
Streaming Delayed Price
Updated: 10:24 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oric Pharmaceuticals Inc
< Previous
1
2
Next >
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
August 12, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
August 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) is a Stock Spotlight on 3/1
March 01, 2024
Via
Investor Brand Network
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
July 16, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
July 09, 2024
From
Attovia Therapeutics, Inc.
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
May 29, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
May 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
April 15, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
April 04, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
March 11, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
March 06, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
February 14, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
January 31, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
January 22, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
January 08, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
December 11, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
November 09, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
November 06, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.